In Pursuance of Differentiation Inducers to Combat Cancer via Targeting of Abnormal Methylation Enzymes

Main Article Content

Ming C. Liau
Jai-Hyun Kim
John P. Fruehauf

Abstract

Cell differentiation agent-2 (CDA-2) was a promising hypomethylating agent approved by the Chinese FDA for the therapy of MDS in China. The active components of CDA-2 are differentiation inducers (DIs) and differentiation helper inducers (DHIs). DIs are chemicals capable of eliminating telomerase from abnormal MEs commonly found in human cancers. The major DI of CDA-2 is an organic acid without UV absorption. Without UV absorption as a guide, it was difficult to purify the DI of CDA-2 for identification. Thus, we pursued possible candidates to function as DIs in this study.

Cancer MEs become abnormal due to association with telomerase. Naturally we sought telomerase inhibitors as possible candidates of DIs. Prostaglandin E2 (PGE2) attracted our attention because it was implicated to involve in wound healing, which is a major biological mission of progenitor stem cells (PSCs) and cancer stem cells (CSCs). Eradication of CSCs has been a major focus of our studies. Besides, PGE2 fits the description of the major DI of CDA-2.

Induction of terminal differentiation (TD) of HL-60 cells by NBT assay was employed to evaluate the activity of chemicals as DIs. Cell growth was based on cell numbers. All-trans retinoic acid (ATRA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) are two well known DIs. ATRA displayed a wide active dosage range from 0.2 to 4.5 µM with a maximum of inducing 89% NBT+ cells at 3 µM. TPA displayed a narrow active dosage range from 0.2 to 0.6 nM with a maximum of inducing 84% NBT+ cells at 0.4 nM. BIBR1532 and bodine were the two telomerase inhibitors studied. Both were found active as DIs. BIBR1532 was active in the dosage range from 30 to 75 µM with a maximum of inducing 86% at 63 µM. Bodine was active in the dosage range from 60 to 98 µM with a maximum of inducing 80% at 98 µM. PGE2 was active in the dosage range from 20 to 70 µM with a maximum of inducing 80% at 56 µM.

DIs at dosages not active as DIs could function as effective DHIs to other DIs. RI0.5 of BIBR1532, boldine and PGE2 as DHIs were 2.02 µM, 3.11 µM, and 0.92 µM, respectively.

DIs alone, no matter how effective, could not induce NBT+ cells to reach 100%. 95% (89% plus 6% of blank) was the highest value achieved by ATRA. Incomplete induction of TD was the reason for frequent recurrence when ATRA was used alone in the therapy of acute promyelocytic leukemia (APL). A combination of ATRA and a DHI could induce NBT+ cells to reach 100% to avoid recurrence.

Keywords:
Differentiation therapy, differentiation inducers, differentiation helper, inducers, methylation enzymes.

Article Details

How to Cite
Liau, M. C., Kim, J.-H., & Fruehauf, J. P. (2020). In Pursuance of Differentiation Inducers to Combat Cancer via Targeting of Abnormal Methylation Enzymes. Journal of Cancer and Tumor International, 10(2), 39-47. https://doi.org/10.9734/jcti/2020/v10i230125
Section
Original Research Article

References

Liau MC, Chang CF, Saunders GF, Tsai YH. S-Adenosylmethionine homocysteine hydrolase as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys. 1981;208(1):261-272.

Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Chin Oncol Cancer Res. 2010;7(2):86-96.

Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. Cancer Res. 1979;39:2113-2119.

Liau MC, Chang CF, Giovanella BC. Demonstration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst. 1980;64:1071-1075.

Prudova A, Bauman Z, Braun A, Vitvitsky V, et al. S-Adenosylmethionine stabilizes cystathionine β-synthase and modulates redox capacity. Proc Natl Acad Sci USA. 2006;103:6489-6494.

Chiba P, Wallner L, Kaizer E. S-adenosylmethionine metabolism in HL-60 cells: Effect of cell cycle and differentiation. Biochim Biophys Acta. 1988;971:38-45.

Tahiliani M, Koh KP, Shen Y, Lawler A, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET 1. Science. 2009;324(5929):930-935.

Ito S, Shen L, Dai Q, Wu SC, et al. Tet protein can convert 5-methycytosine to 5-formylcytosine and 5-carboxycytosine. Science. 2011;333(6047):1300-1303.

Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: Potential implication for active demethylation of CpG sites. J Biol Chem. 2011;286(41):35334-35338.

Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103(4):670-676.

Ficz GM, Gibben JG. Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? Genomics. 2014;104(5): 352-357.

Wang KC, Kang CH, Tsai CY, Chou NH, et al. Ten-eleven translocation 1 dysfunction reduces 5-hydroxymethylcytosine expression in gastric cancer cells. Oncol Lett. 2018;15(1):278-284.

Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells; 2019.

DOI: 10.33552/OJCAM.2019.02.000546

Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1987;13(Suppl. 1):77-82.

Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stud Ther J. 2019;4(1):1-15.

El-Daly H, Kull M, Zimmerman S, et al. Selective toxicity and telomerase in leukemic cells using telomerase inhibitor BIBR1532. Blood. 2005;195:1742-1749.

Ganesan K, Xu P. Telomerase inhibitors from natural products and their anticancer potential. Int J Mol Sci. 2018;9(1):13.

DOI: 10.3390/ijms 19010013

Ho ATV, Palla AR, Blake MR, Yual ND. Prostaglandin E2 is essential for efficacious skeletal muscle stem cell function, augmenting regeneration and strength. Proc Natl Acad Sci USA. 2017;114(26):6675-6684.

Liau MC, Liau CP, Burzynski SR. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Exptl Clin Chemother. 1992;5:9-17.

Liau MC, Huang LJ, Lee JH, Chen SC, et al. Development of differentiation helper inducers for differentiation therapy of cancer. Chin Pharm J. 1998;50:289-303.

Liau MC, Liau CP. Methyltransferase inhibitors as excellent differentiation helper inducers for differentiation therapy of cancer. Bull Chin Cancer. 2002;11:166-168.

Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting methylation enzymes. J Pharmacol Pharmaceu Pharmacovigi. 2019;3:009.

DOI: 10.24966/PPP-5649/100009

Woll PS, Kjallquist U, Chowdhury O, Doolittle H, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25:794-808.

Huang M, Ye Y, Chen Z, Chai JR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72:567-572.

De The H, Pandeifi PP, Chen Z. Acute promyelocytic leukemia: A paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;5:552-560.

Bourgeade MF, Besancon F. Induction of 2’,5’-oligoadenylate synthetase by retinoic acid in two transformed human cell lines. Cancer Res. 1984;44:5355-5360.

Riciotti E, FitzGerald GA. Prostaglandin and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000.

Wilson JN, Potten CS. The effect of exogenous prostaglandin administration on tumor size and yield in min/+ mice. Cancer Res. 2000;60(16):4645-4653.